Reg. Office.: Office No # 812, Anand Mangal – III, Opposite Core house, Near Hirabag,
Near Rajnagar Club, Ambawadi, Ahmedabad-06 | CIN: L24230GJ1995PLC026244
Email: tohealpharmachem@gmail.com | Phone – 9773151363 | Website: https://www.mcom18.com/

Ref No: - MADHUVEER/SEC/STOCK/2024-25

Date: 11/02/2025

To,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai - 400 001.

SECURITY CODE: 531910 || SECURITY ID: MADHUVEER || ISIN: INE312M01016 || SERIES: EQ

Dear Sir/Madam,

Sub.:- Outcome of Board Meeting held today i.e. on 11th February, 2025 and submission of Standalone and Consolidated Un-audited Financial Results of the Company for the Quarter and Nine Months ended on 31st December, 2024.

With reference to our previous communications through letter dated 04th February, 2025 regarding the date of Board Meeting and business to be transacted thereat etc., and in continuation to the same, this is to inform you that the Meeting of Board of Directors commenced at 5.30 p.m. today and has inter alia considered the following:

- Pursuant to review and recommendation of Audit Committee of the Company the Board has
  considered and approved Standalone and Consolidated Un-audited Financial Results of the
  Company along with Limited Review Reports for the quarter and Nine Months ended on
  31st December, 2024 of the current financial year 2024-25, pursuant to Regulation 33 of the
  Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
  Regulations, 2015 ("SEBI LODR Regulations").
- 2. Pursuant to recommendation of Nomination and Remuneration Committee of the Company, the Board has approved Re-appointment of Mr. Dipankar Bhuvneshwar Mahto (DIN: 08730286) as an Independent Director for a second term of five years, i.e., from March 21, 2025 to March 20, 2030.

Mr. Dipankar Bhuvneshwar Mahto has confirmed that they meet the criteria of 'independence' under Section 149 of the Companies Act, 2013, and Regulation 16 of the Listing Regulations. Further, he has also confirmed that they have not been debarred from holding the office of Director by virtue of any Order passed by the Securities and Exchange Board of India or any other such authority.

The disclosures required under Regulation 30 of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, concerning the above reappointments, are attached as "Annexure- A".

- 3. Appointment Mr. Rahul Sen, as Internal Auditor for FY 2024-25, the brief information as required under Regulation 30 of SEBI (LODR) regulations, 2015 for the said matter is attached as "Annexure-B".
- 4. Appointment of Ms. Shilpa Shah (Practicing Company Secretary), as Secretarial Auditor for FY 2024-25, The brief information as required under Regulation 30 of SEBI (LODR) regulations, 2015 for the said matter is attached as "Annexure-C".

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag,
Near Rajnagar Club, Ambawadi, Ahmedabad-06 | CIN: L24230GJ1995PLC026244
Email: tohealpharmachem@gmail.com | Phone - 9773151363 | Website: https://www.mcom18.com/

The meeting of the Board of Directors concluded at 6.45 p.m.

You are therefore requested to take note of the same.

Thanking you,

Yours faithfully,

For, Madhuveer Com 18 Network Limited

Manorama Shah Director DIN: 07108562



Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag,
Near Rajnagar Club, Ambawadi, Ahmedabad-06 | CIN: L24230GJ1995PLC026244
Email: tohealpharmachem@gmail.com | Phone - 9773151363 | Website: https://www.mcom18.com/

#### Annexure -A

#### BRIEF PROFILE OF MR. DIPANKAR MAHTO AS INDEPENDENT DIRECTOR

Sr. No.	Particulars	Information			
1	Name of Independent Director	Mr. Dipankar Bhuvneshwar Mahto			
2	Reason for change viz. appointment, resignation removal, death or otherwise	Re-appointment: Mr. Dipankar Bhuvneshwar Mahto is Reappointed as a Non-Executive, Independent Director of the company.			
3	Date of Re-appointment and term of re-appointment	Re-appointment as Non-Executive, Independent Director for a second term of 5 (five) years effective March 21, 2025 till March 20, 2030, subject to the approval of the members.			
4	Brief Profile (in case of appointment)	Mr. Dipakar Mahto has acquired comprehensive knowledge in business management, equipping him with the expertise to serve as a valuable advisor to the board of directors and senior management. His insights can guide strategic decision-making and support the overall growth and efficiency of the company.			
5	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Dipankar Bhuvneshwar Mahto is not related to any of the Directors of the Company.			

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag,
Near Rajnagar Club, Ambawadi, Ahmedabad-06 | CIN: L24230GJ1995PLC026244
Email: tohealpharmachem@gmail.com | Phone - 9773151363 | Website: https://www.mcom18.com/

# Annexure -B BRIEF PROFILE OF MR. RAHUL SEN AS INTERNAL AUDITOR

Sr.	Particulars	Information
No.		
1	Name of Internal Auditor	Mr. Rahul Sen
2	Reason for change viz. appointment, resignation removal, death or otherwise	Appointment of Internal Auditor for FY 2024-25.
3	Date of Appointment	February 11, 2025
4	Term of Appointment	Mr. Rahul Sen, Ahmedabad being the Internal Auditors are appointed by the Board of Directors of the Company, to conduct the Internal Audit of the records of the Company for the financial year ending 31st March 2025.
5	Brief Profile (in case of appointment)	Mr. Rahul Sen has extensive experience of over seven years in the fields of accounting and internal controls, where he has consistently demonstrated his expertise in managing financial operations, ensuring compliance, and implementing effective control measures to safeguard organizational assets.
6	Disclosure of relationships between directors (in case of appointment of a director)	NA

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag,
Near Rajnagar Club, Ambawadi, Ahmedabad-06 | CIN: L24230GJ1995PLC026244
Email: tohealpharmachem@gmail.com | Phone - 9773151363 | Website: https://www.mcom18.com/

#### Annexure -C

#### BRIEF PROFILE OF MS. SHILPA SHAH AS SECRETARIAL AUDITOR

Sr. No.	Particulars	Information
1	Name of Secretarial Auditor	Ms. Shilpa Shah
2	Reason for change viz. appointment, resignation removal, death or otherwise	Appointment of Secretarial Auditor for FY 2024- 25.
3	Date of Appointment	February 11, 2025
4	Term of Appointment	Ms. Shilpa Shah, Practicing Company Secretary (COP No: 27483) as the Secretarial Auditor of the Company to conduct the secretarial audit of the of the Company for the financial year ending 31st March, 2025.
5	Brief Profile (in case of appointment)	Ms. Shilpa Shah, Practicing Company Secretary is registered with the Institute of Company Secretaries of India. Ms. Shilpa Shah, having Certificate of Practice Number 27483 has rich and varied experience in Corporate Law matters. She is based at Ahmedabad. The core competency of her lies under the Companies Act, 2013, SEBI Regulations, FEMA, NBFC and other allied Corporate Laws.
6	Disclosure of relationships between directors (in case of appointment of a director)	NA

CIN: L93000GJ1995PLC026244

Regd. Off: No #812, Anand Mangal - III, Opp. Core House, Ambawadi, Ahmedabad - 380006

Email: tohealpharmachem@gmail.com

#### STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED DECEMBER 31, 2024

(Rs. in Lakhs except EPS)

٠,		Standalone					
Sr. No.	Particulars	Quarter Ended			Nine Mor	nth Ended	Year Ended
140.		(31/12/2024)	(30/09/2024)	(31/12/2023)	(31/12/2024)	(31/12/2023)	(31/03/2024)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue From Operations	71.80	-	4.53	71.80	19.62	221.86
	(b) Other income	-	26.85	-	52.85	-	201.50
	Total Income (a+b)	71.80	26.85	4.53	124.65	19.62	423.36
2	Expenses						
	(a) Cost of materials consumed	0.05	-	-	0.05	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods,	-	-	-	-	-	-
	work-in-progress and stock-in-trade						
	(d) Employee benefits expense	0.90	1.79	1.01	4.69	3.03	4.04
	(e) Finance Cost	1.81	-	-	2.47	-	1.37
	(f) Depreciation and amortisation expense	0.97	0.17	0.11	1.31	0.33	1.10
	(g) Other expenses	2.96	7.21	1.02	17.51	33.67	48.84
	Total expenses	6.69	9.16	2.14	26.03	37.03	55.36
3	Profit / (Loss) from Operations before exceptional and tax	65.11	17.68	2.38	98.62	(17.41)	368.00
	(1-2)	03.11	17100	2.55	30102	(27.1.2)	300100
4	Less: Exceptional items	-	-	-		-	-
5	Profit / (Loss) before tax (3-4)	65.11	17.68	2.38	98.62	(17.41)	368.00
6	Tax expense						
	- Current Tax	16.17	4.40	-	24.63	-	92.79
	- Tax of Ealier Perioud	-	-	-		-	-
	- Deferred Tax	(1.15)	0.07	0.01	(1.18)	0.02	(0.14)
7	Net Profit (Loss) after tax (5-6)	50.09	13.21	2.38	75.17	(17.43)	275.35
	THE CONTROL (2005) WHICH CAN (3 0)	20,02			75121	(=::::)	
8	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss:	-	-	-		-	-
	Remeasurement of defined benefits plans (net of tax)						
9	Total Comprehensive Income/(Loss) (after tax) for the	F	40			4.7	275
	period (9+10)	50.09	13.21	2.38	75.17	(17.43)	275.35
10	Paid up Equity Share Capital (Face value of Re. 10/- each)	2,448.07	2,448.07	948.07	2,448.07	948.07	948.07
	rate up Equity Share capital (race value of ite. 10) - each)	2,770.07	2,110.07	3-10.07	2,440.07	340107	340.07
11	Other Equity excluding revaluation reserve		-	_			
	Equity Environing resumment reserve						
12	Earnings per equity share:						
	(1) Basic	0.20	0.05	0.03	0.31	(0.18)	2.90
	(2) Diluted	0.20	0.05	0.03	0.31	(0.18)	1.75
	12/ 2/10/20	3.20	5.05	3.03	3.31	(3.10)	1.73

- 1 The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 11th February, 2025.
- 2 The Unaudited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- 3 During the quarter ended 31st December, 2024, 0 complaints was received and 0 complaint for last quarter attended and closed.
- 4 Previous quarter's figures have been re-grouped / re-arranged wherever necessary.



By Order of the Board of Directors For Madhuveer Com 18 Network Limited

**Dhruvin Shah** Managing Director DIN:07108562

Date: 11/02/2025 Place : Ahmedabad



INDEPENDENT AUDITOR'S REVIEW REPORT on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
Madhuveer Com 18 Network Limited,
Ahmedabad

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Madhuveer Com 18 Network Limited (the "Company"), for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: 11/02/2025

UDIN: 25133926BMJGPB9724

**FOR MAAK and Associates** 

[Firm Registration No.135024W]

FRN: 135024W AHMEDABAD

Chartered Accountants

Marmik Shah

Partner

Mem. No. 133926

CIN: L93000GJ1995PLC026244

Regd. Off: No # 812, Anand Mangal - III, Opp. Core House, Ambawadi, Ahmedabad - 380 006

Email: tohealpharmachem@gmail.com

(Rs. In Lakhs)

#### Statement of Unaudited Consolidated Results for the Quarter and Nine month ended as on 31st December, 2024

Sr. No. Particulars  1 Income (a) Revenue From Operations (b) Other income Total Income (a+b)  2 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense		Consolidated						
1 Income (a) Revenue From Operations (b) Other income Total Income (a+b)  2 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense			Quarter Ended		Nine Mon	th Ended	Year Ended	
(a) Revenue From Operations (b) Other income Total Income (a+b)  2 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense	(:	31/12/2024)	(30/09/2024)	(31/12/2023)	(31/12/2024)	(31/12/2023)	(31/03/2024)	
(a) Revenue From Operations (b) Other income Total Income (a+b)  2 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
(b) Other income  Total Income (a+b)  2 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense		` '	` '		,	,		
Total Income (a+b)  2 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense		227.84	64.06	4.52	295.85	19.62	485.05	
2 Expenses (a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense		96.82	27.05	0.81	152.51	1.21	207.04	
(a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense		324.67	91.11	5.32	448.36	20.83	692.09	
(a) Cost of materials consumed (b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense								
(b) Purchase of stock-in-trade (c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense								
(c) Changes in inventories of finished work-in-progress and stock-in-trade (d) Employee benefits expense		0.07	-		0.07	-	-	
work-in-progress and stock-in-trade (d) Employee benefits expense		-	-		-	-	-	
(d) Employee benefits expense	goods,	-	-		-	-	-	
		-	-			-	-	
		47.22	40.47	1.01	123.54	3.03	110.61	
(e) Finance Cost		0.62	1.47		2.89	-	3.89	
(f) Depreciation and amortisation exp	pense	83.40	78.84	0.11	233.63	0.33	93.64	
(g) Other expenses		63.85	56.62	1.95	156.74	34.64	186.98	
Total expenses		195.17	177.40	3.08	516.87	38.01	395.11	
3 Profit / (Loss) from Operations befor and tax (1-2)	re exceptional	129.50	(86.29)	2.25	(68.51)	(17.18)	296.98	
A Lass Sussession of items								
4 Less: Exceptional items			-				-	
5 Profit / (Loss) before tax (3-4)		129.50	(86.29)	2.25	(68.51)	(17.18)	296,98	
3 Figure (2033) before tax (3-4)		129.50	(80.29)	2.23	(08.51)	(17.10)	290.96	
6 Tax expense								
- Current Tax		16.17	4.36	(0.10)	24.70		92.87	
- Tax of Ealier Perioud		10:17	4,50	(0.10)	-		52.07	
- Deferred Tax		13.92	(26.00)	0.01	78.57	0.02	(29.58	
Deterred rax		13.52	(20.00)	0.01	70.57	0.02	(25.50	
7 Net Profit (Loss) after tax (5-6)		99.41	(64.65)	2.34	(171.78)	(17.19)	233.69	
Net Fiorit (Loss) after tax (3-0)		33.41	(04.03)	2.34	(171.76)	(17.15)	233.09	
8 Other Comprehensive Income								
Items that will not be reclassified to I	Profit or Loss:					_		
Remeasurement of defined benefits p	I							
9 Total Comprehensive Income/(Loss) period (9+10)	(after tax) for the	99.41	(64.65)	2.34	(171.78)	(17.19)	233.69	
10 Paid up Equity Share Capital (Face va	alue of Re. 10/-	2,448.07	2,448.07	948.07	2,448.07	948.07	948.07	
11 Other Equity excluding revaluation r	reserve					-	-	
12 Earnings per equity share:				+				
(1) Basic		0.41	(0.26)	0.02	(1.81)	(0.18)	2.46	
(2) Diluted	ı	0.41	(0.26)	0.02	(1.81)	(0.18)	1.49	

#### Notes:

- 1 The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 11th February, 2025.
- 2 The Unaudited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- 3 During the quarter ended 31st December, 2024, 0 complaints was received and 0 complaint for last quarter attended and closed.
- 4 Previous quarter's figures have been re-grouped / re-arranged wherever necessary.



By Order of the Board of Directors For Madhuveer Com 18 Network Limited

Date: 11/02/2025 Place : Ahmedabad Dhruvin Shah Managing Director DIN:07108562



INDEPENDENT AUDITOR'S REVIEW REPORT on Consolidated Unaudited Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
Madhuveer Com 18 Network Limited,
Ahmedabad

- 1. We have reviewed the accompanying statement of unaudited Consolidated financial results of Madhuveer Com 18 Network Limited (the "Company") and its associates (the Holding Company and its subsidiary together referred to as "the Group") which comprises the Consolidated Statement of Profit and Loss and for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

- 4. The Statement includes the results of the following entities:
  - 1) Sakshi barter Private Limited
  - 2) Navkar Events Private Limited
- 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. Emphasis of Matter No Such thing requires to be mentioned hence our conclusion is not modified in respect of this matter.
- 7. The Consolidated Unaudited Financial Results includes the Interim Financial Results of two subsidiary, which have been reviewed by us, whose Interim Financial results reflect total revenue of Rs. 323.71 Lakhs and total net profit / (loss) after tax of Rs. (246.94) Lakhs and total comprehensive income / loss of Rs. (246.94) for for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024, as considered in the Consolidated Unaudited Financial Results.

Our conclusion on the statement is not modified in respect of the above matters.

**FOR MAAK and Associates** 

[Firm Registration No.135024W]

FRN: 135024W AHMEDABAD

Chartered Accountants

Marmik Shah

Partner

Mem. No. 133926

Place: Ahmedabad Date: 11/02/2025

UDIN: 25133926BMJGPC4601